Jazz Pharmaceuticals PLC $JAZZ Stock Acquired by Sigma Planning Corp

Sigma Planning Corp boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 205.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,128 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,119 shares during the quarter. Sigma Planning Corp’s holdings in Jazz Pharmaceuticals were worth $1,419,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. USA Financial Formulas purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth about $25,000. Pension & Wealth Management Advisors Inc. bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $32,000. Ameritas Advisory Services LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $47,000. Westpac Banking Corp purchased a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at about $51,000. Finally, Root Financial Partners LLC raised its holdings in shares of Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 89 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on JAZZ shares. Barclays boosted their target price on Jazz Pharmaceuticals from $270.00 to $271.00 and gave the stock an “overweight” rating in a research report on Thursday, September 10th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. Morgan Stanley decreased their price target on shares of Jazz Pharmaceuticals from $322.00 to $314.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 21st. Robert W. Baird lifted their price target on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $292.05.

Insiders Place Their Bets

In other news, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $249.70, for a total value of $19,207,173.70. Following the sale, the executive vice president directly owned 65,686 shares in the company, valued at approximately $16,401,794.20. This trade represents a 53.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total value of $472,800.00. Following the transaction, the chief executive officer directly owned 141,394 shares in the company, valued at $33,425,541.60. This trade represents a 1.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 100,121 shares of company stock valued at $24,855,802 in the last 90 days. 4.10% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $205.06 on Thursday. The company has a market cap of $13.31 billion, a price-to-earnings ratio of 14.14, a price-to-earnings-growth ratio of 0.26 and a beta of 0.37. The company has a 50-day moving average price of $233.50 and a 200-day moving average price of $215.75. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 12 month low of $128.80 and a 12 month high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($8.25) earnings per share. As a group, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 10.97 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.